Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Walter B, Schrettenbrunner I, Vogelhuber M, Grassinger J, Bross K, Wilke J, Suedhoff T, Berand A, Wieland WF, Rogenhofer S, Andreesen R, Reichle A. Walter B, et al. Among authors: vogelhuber m. Med Oncol. 2012 Jun;29(2):799-805. doi: 10.1007/s12032-011-9982-0. Epub 2011 May 24. Med Oncol. 2012. PMID: 21607771 Clinical Trial.
Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.
Vogelhuber M, Feyerabend S, Stenzl A, Suedhoff T, Schulze M, Huebner J, Oberneder R, Wieland W, Mueller S, Eichhorn F, Heinzer H, Schmidt K, Baier M, Ruebel A, Birkholz K, Bakhshandeh-Bath A, Andreesen R, Herr W, Reichle A. Vogelhuber M, et al. Cancer Microenviron. 2015 Apr;8(1):33-41. doi: 10.1007/s12307-014-0161-7. Epub 2014 Dec 11. Cancer Microenviron. 2015. PMID: 25503648 Free PMC article.
Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.
Vogelhuber M, Feyerabend S, Stenzl A, Suedhoff T, Schulze M, Huebner J, Oberneder R, Wieland W, Mueller S, Eichhorn F, Heinzer H, Schmidt K, Baier M, Ruebel A, Birkholz K, Bakhshandeh-Bath A, Andreesen R, Herr W, Reichle A. Vogelhuber M, et al. Cancer Microenviron. 2015 Apr;8(1):43-4. doi: 10.1007/s12307-015-0165-y. Cancer Microenviron. 2015. PMID: 25651886 Free PMC article. No abstract available.
Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial.
Hart C, Vogelhuber M, Hafner C, Landthaler M, Berneburg M, Haferkamp S, Herr W, Reichle A. Hart C, et al. Among authors: vogelhuber m. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):e119-e121. doi: 10.1111/jdv.13391. Epub 2015 Sep 29. J Eur Acad Dermatol Venereol. 2016. PMID: 26417987 Free PMC article. Clinical Trial. No abstract available.
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Walter I, Schulz U, Vogelhuber M, Wiedmann K, Endlicher E, Klebl F, Andreesen R, Herr W, Ghibelli L, Hackl C, Wiest R, Reichle A. Walter I, et al. Among authors: vogelhuber m. Med Oncol. 2017 Nov 2;34(12):192. doi: 10.1007/s12032-017-1040-0. Med Oncol. 2017. PMID: 29098441 Free PMC article. Clinical Trial.
46 results